Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18824839 | System and Method for Planning and Simulating a Surgical Operation to Create a Patient-Specific Spinal Implant | September 2024 | March 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18692344 | ANALYTIC PLATFORM USING NPM1-ASSOCIATED GENES INTERACTION NETWORK FOR IDENTIFYING GENETIC TRAITS | March 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18163149 | MARKERS FOR THE EARLY DETECTION OF COLON CELL PROLIFERATIVE DISORDERS | February 2023 | March 2025 | Allow | 25 | 4 | 0 | Yes | No |
| 17805147 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR IMPROVING BASE CALLING ACCURACY | June 2022 | May 2025 | Abandon | 35 | 3 | 0 | No | No |
| 17529694 | NORMALIZING TUMOR MUTATION BURDEN | November 2021 | March 2025 | Allow | 40 | 4 | 0 | No | No |
| 17387830 | METHODS AND SYSTEMS FOR ADJUSTING TUMOR MUTATIONAL BURDEN BY TUMOR FRACTION AND COVERAGE | July 2021 | December 2024 | Allow | 41 | 4 | 0 | No | No |
| 17304066 | METHOD, APPARATUS AND COMPUTER PROGRAM PRODUCT FOR PROVIDING A MULTI-OMICS FRAMEWORK FOR ESTIMATING TEMPORAL DISEASE TRAJECTORIES | June 2021 | March 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17281707 | METHOD AND SYSTEM OF TARGETING EPITOPES FOR NEOANTIGEN-BASED IMMUNOTHERAPY | March 2021 | May 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17207169 | MACHINE LEARNING DRIVEN GENE DISCOVERY AND GENE EDITING IN PLANTS | March 2021 | November 2024 | Allow | 44 | 3 | 0 | Yes | No |
| 17261707 | Method of Performing Differential Diagnosis of Neurodegenerative Diseases in a Subject | January 2021 | March 2025 | Abandon | 50 | 1 | 0 | No | No |
| 17128298 | ELECTRON DENSITY ESTIMATION METHOD, ELECTRON DENSITY ESTIMATION APPARATUS, AND RECORDING MEDIUM | December 2020 | June 2025 | Abandon | 54 | 2 | 1 | Yes | No |
| 17126491 | Merging Alignment and Sorting to Optimize Computer Operations for Gene Sequencing Pipeline | December 2020 | May 2025 | Allow | 53 | 2 | 0 | Yes | No |
| 17112956 | Rapid Detection of Gene Fusions | December 2020 | April 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 15734674 | SYSTEM, METHOD, AND COMPUTER PROGRAM PRODUCT FOR PREDICTING PROPERTIES OF A POLYMER | December 2020 | December 2024 | Abandon | 49 | 1 | 0 | No | No |
| 17068311 | SYSTEMS AND METHODS FOR IDENTIFYING POSITIVE ALLOSTERIC MODULATORS OF ENZYMES TO ENHANCE ACTIVITY | October 2020 | February 2025 | Allow | 52 | 2 | 0 | Yes | No |
| 17040620 | METHODS FOR SCREENING A SUBJECT FOR THE RISK OF CHRONIC KIDNEY DISEASE AND COMPUTER-IMPLEMENTED METHOD | September 2020 | January 2025 | Abandon | 52 | 2 | 0 | No | No |
| 16982290 | COSMOPLEX: SELF-CONSISTENT SIMULATION OF SELF-ORGANIZING SYSTEMS | September 2020 | May 2025 | Allow | 56 | 3 | 0 | No | No |
| 16990464 | SCORING VARIANTS IN AN EXOME TO PREDICT AN EFFECT OF THE VARIANTS ON GENE FUNCTION | August 2020 | May 2025 | Abandon | 57 | 4 | 0 | No | No |
| 16945052 | METHODS FOR CONTROL OF A SEQUENCING DEVICE | July 2020 | March 2025 | Abandon | 55 | 4 | 0 | No | No |
| 16963803 | EXERCISE LOAD ESTIMATION METHOD, EXERCISE LOAD ESTIMATION DEVICE, AND RECORDING MEDIUM | July 2020 | April 2025 | Abandon | 57 | 3 | 0 | No | No |
| 16908581 | DEVICES AND METHODS FOR GENOME SEQUENCING | June 2020 | December 2024 | Allow | 53 | 4 | 0 | Yes | No |
| 16652555 | DETERMINING FUNCTIONAL STATUS OF IMMUNE CELLS TYPES AND IMMUNE RESPONSE | March 2020 | June 2025 | Allow | 60 | 5 | 0 | No | No |
| 16749737 | Pharmacogenomic Decision Support for Modulators of the NMDA, Glycine, and AMPA Receptors | January 2020 | February 2024 | Allow | 49 | 3 | 0 | Yes | No |
| 16653564 | Re-writable DNA-Based Digital Storage with Random Access | October 2019 | January 2025 | Allow | 60 | 2 | 0 | Yes | No |
| 16532077 | SYSTEMS AND METHODS FOR STORING AND READING NUCLEIC ACID-BASED DATA WITH ERROR PROTECTION | August 2019 | September 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16478818 | NEOANTIGENS AND USES THEREOF FOR TREATING CANCER | July 2019 | November 2024 | Allow | 60 | 3 | 1 | No | No |
| 16345367 | SYSTEMS AND METHODS FOR ULTRA-FAST IDENTIFICATION AND ABUNDANCE ESTIMATES OF MICROORGANISMS USING A KMER-DEPTH BASED APPROACH AND PRIVACY-PRESERVING PROTOCOLS | April 2019 | August 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16307817 | SYSTEMS AND METHODS FOR INTERPOLATION IN SYSTEMS WITH NON-LINEAR QUANTIZATION | December 2018 | October 2024 | Abandon | 60 | 4 | 1 | No | No |
| 14895746 | BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING | December 2015 | March 2025 | Allow | 60 | 13 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner NEULEN, EMILIE ALINE works in Art Unit 1686 and has examined 27 patent applications in our dataset. With an allowance rate of 66.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 53 months.
Examiner NEULEN, EMILIE ALINE's allowance rate of 66.7% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NEULEN, EMILIE ALINE receive 3.33 office actions before reaching final disposition. This places the examiner in the 98% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by NEULEN, EMILIE ALINE is 53 months. This places the examiner in the 0% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +49.5% benefit to allowance rate for applications examined by NEULEN, EMILIE ALINE. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 24.3% of applications are subsequently allowed. This success rate is in the 26% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 11.1% of cases where such amendments are filed. This entry rate is in the 6% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 96% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.